News By Tag
* Target-focused Libraries
* Drug-like Compounds
* Fluorescent Dyes
* Combinatorial Synthesis
* Selective Inhibitors
* More Tags...
News By Location
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD.
Otava offers 29 Alzheimer’s disease Targeted Libraries designed with Ligand-based and Receptor-based approach. These libraries contain only drug-like compounds. All molecules have enhanced potential for CNS bioavailability. Filtering by polar surface area parameter (PSA) which discriminates CNS penetrating compounds, we selected only those compounds having increased blood-brain barrier (BBB) permeability.
In this collection of targeted libraries we included those activities which can be divided into two Alzheimer’s treatment categories: (i) disease-modifying treatments that target and reduce the secondary pathologies of the disease, leading to the cessation or the reversal of disease progression;
We hope that Otava Targeted Libraries can help scientists and pharmaceutical companies racing to develop treatments that address the underlying Alzheimer’s disease processes.
P.O. Box 88
Kyiv 187, 03187
# # #
OTAVA Ltd. is an international science-based chemical company founded in 1997. It has production laboratories and offices in Europe (Kiev, Ukraine) and North America (Toronto, Canada).